Skip to main content
. 2021 Dec 18;107(5):1461–1469. doi: 10.1210/clinem/dgab905

Figure 3.

Figure 3.

Efficacy outcomes of semaglutide 2.0 mg vs dulaglutide 3.0 mg and 4.5 mg using SUSTAIN 7 results corresponding to week 36. Change in HbA1c from baseline (A); change in bodyweight (kg) from baseline (B); proportion of patients achieving target HbA1c (C). Main analysis, sensitivity analyses 1 and 2. Abbreviations: Crl, credible interval; ETD, estimated treatment difference; HbA1c, glycated hemoglobin; OR, odds ratio.